Company: CRVO
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001437749-25-013543
Chunk: 33

Company: CervoMed Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 33
---
 Committee that our consolidated financial statements were prepared in accordance with generally accepted accounting principles. The Audit Committee has discussed with RSM US LLP, our independent registered public accounting firm for the year ended December 31, 2024, the matters required to be discussed under Public Company Accounting Oversight Board standards. The Audit Committee has received the written disclosures and the letter from our independent registered public accounting firm required by the applicable requirements of the Public Company Accounting Oversight Board regarding communications with audit committees concerning independence. The Audit Committee has discussed with RSM US LLP its independence and concluded that the independent registered public accounting firm is independent from our Company and our management.

Based on the review and discussions of the Audit Committee described above, the Audit Committee recommended to the Board that our audited consolidated financial statements for the year ended December 31, 2024, be included in our Annual Report for the year ended December 31, 2024, for filing with the SEC.

Audit Committee
Jeff Poulton, Chair
Jane H. Hollingsworth, J.D.
Frank Zavrl

<div align='center'>16

EXECUTIVE OFFICERS</div>

The table below sets forth, as of the date of this Proxy Statement, certain information concerning our executive officers who are also not directors. Biographical information for Drs. Alam and Cobuzzi is included under the heading, “Corporate Governance—Our Board of Directors”. On April 14, 2025, the Board approved the terms of the Separation Agreement with Dr. Cobuzzi, pursuant to which his employment with the Company will conclude effective July 1, 2025.

| Name                        |     | Age |     | Position with CervoMed                                                             |
| William R. Elder            |     |  42 |     | Chief Financial Officer, General Counsel & Corporate Secretary                     |
| Kelly Blackburn, M.H.A.     |     |  61 |     | Executive Vice President, Clinical Development                                     |
| Mark De Rosch, Ph.D., FRAPS |     |  61 |     | Executive Vice President, Regulatory and Government Affairs and Program Management |

William Elder has served as the Company’s General Counsel & Corporate Secretary since September 2020 and as the Company’s Chief Financial Officer since June 2024. Mr. Elder has also served as our Principal Financial Officer since March 2024, previously served as Diffusion’s Principal Financial Officer from June 2023 to August 2023 and also served as a part-time consultant to Diffusion from July 202